Inventiva S.A. IVEVF

IVEVF Company Overview

Inventiva S.A. is a French clinical-stage biopharmaceutical company focused on the research and development of oral small-molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), rare diseases, and other conditions with significant unmet medical need. The company operates within the biotechnology and pharmaceutical industries and is publicly traded on Euronext Paris and the Nasdaq Global Market under the ticker IVA. Its primary value driver is the development of lanifibranor, a pan-PPAR agonist being evaluated for the treatment of MASH, a chronic liver disease associated with fibrosis and metabolic disorders.

The company was founded in 2012 as a spin-off from AbbVie’s French research operations following AbbVie’s acquisition of Abbott Laboratories’ pharmaceutical business. Inventiva inherited research infrastructure and scientific programs centered on nuclear receptor biology and fibrosis-related diseases. Over time, the company narrowed its strategic focus toward liver disease and fibrosis therapeutics, positioning itself within a competitive but rapidly expanding market for metabolic and hepatology treatments. Inventiva has also maintained selective research collaborations and out-licensing arrangements to support financing and scientific development.